Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT00613496
Other study ID # AG-1-2007
Secondary ID EUDRACTN: 2007-0
Status Recruiting
Phase Phase 4
First received January 31, 2008
Last updated May 28, 2009
Start date May 2009
Est. completion date May 2010

Study information

Verified date May 2009
Source University of Magdeburg
Contact Andreas Goette, MD
Phone 00493916713225
Email andreas.goette@medizin.uni-magdeburg.de
Is FDA regulated No
Health authority Germany: Federal Institute for Drugs and Medical Devices
Study type Interventional

Clinical Trial Summary

Experimental data suggest that angiotensin II-antagonists reduce the atrial expression of prothrombotic adhesion molecules and oxidative stress parameters. The present study is designed to investigate the effects on angiotensin II-antagonist irbesartan to reduce the amounts of circulating oxidative stress markers and adhesion molecules in patients with persistent atrial fibrillation.


Description:

Primary Objective:

The aim of the study is to assess that blocking the angiotensin II type 1 receptor reduces systemic levels of oxidative stress markers and adhesion molecules by more than 25% compared to placebo in patients with persistent/permanent atrial fibrillation.

Primary Target Parameter:

The primary target parameter is defined as reduction of systemic levels of oxidative stress markers and adhesion molecules (hsCRP, ICAM, VCAM, MCP-1, vWF, TGFβ1, TNF-α, Interleukin-6, 8isoProstaglandinF2α)

Secondary Target Parameter:

The secondary Target Parameters are defined as number of cerebrovascular events, number of intermediate medical visits for cardiovascular reasons without hospitalisation, number of hospitalisations for cardiovascular reasons and GFR.


Recruitment information / eligibility

Status Recruiting
Enrollment 60
Est. completion date May 2010
Est. primary completion date May 2010
Accepts healthy volunteers No
Gender Both
Age group 18 Years and older
Eligibility Inclusion Criteria:

- Patients with persistent/permanent AF (>2 months)

- CHADS2 Score =2

- Age =18

- Patient informed orally and in writing

- Written informed consent of the patient

- Patients who are anticipated to show sufficient compliance in following the study protocol

- Patients must agree to undergo the 148 days clinical follow-up

- Patients who are mentally and linguistically able to understand the aim of the study and the associated risks and benefits of the treatment. The patients, by providing informed consent, agree to this treatment as stated in the patient informed consent document.

Exclusion Criteria:

- Strong clinical evidence that prevents the temporary pause of therapy with AT II antagonists

- Symptomatic bradycardia

- Implanted pacemaker or implanted cardioverter/defibrillator with any antitachycardia algorithm in use

- Cardiac surgery or cardiac catheter ablation within the last 3 months prior to randomisation

- Typical angina pectoris symptoms at rest or during exercise

- Known coronary artery disease with indication for intervention

- Symptomatic peripheral vascular disease

- Left ventricular ejection fraction <35%

- Myocardial infarction within 6 months prior to randomisation

- Diastolic blood pressure >110mmHg at rest

- Symptomatic arterial hypotension

- Known renal artery stenosis

- Serum creatinin >1.8mval/l

- Chronic inflammatory disease

- Acute inflammatory disease (CRP >20mg/L)

- Relevant hepatic or pulmonary disorders

- Hyperthyreosis manifested clinically and in laboratory

- Known drug intolerance for AT II inhibitors

- Females who are pregnant or breast feeding

- Females of childbearing potential who are not using a scientifically accepted method of contraception

- Participation in a clinical trial within the last 30 days prior to randomisation

- Drug addiction or chronic alcohol abuse

- Cancer or other disease, which inevitably leads to death

- Legal incapacity, or other circumstances which would prevent the patient from understanding the aim, nature or extent of the clinical study, evidence of an uncooperative attitude

Study Design

Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment


Related Conditions & MeSH terms


Intervention

Drug:
irbesartan
Irbesartan-tablet (150 mg) 1 in the morning for 7 days, 2 tablets (1 in the morning and 1 in the evening) after day 8 if no contraindication for up titration (investigator will decide on the basis of creatinin, urea and potassium after taking a blood sample) for 9 weeks.
placebo
Placebo-tablet, 1 in the morning for 7 days, 2 tablets (1 in the morning and 1 in the evening) after day 8.

Locations

Country Name City State
Germany University Hospital Magdeburg; Div. of Cardiology Magdeburg

Sponsors (2)

Lead Sponsor Collaborator
University of Magdeburg Sanofi

Country where clinical trial is conducted

Germany, 

Outcome

Type Measure Description Time frame Safety issue
Primary The primary target parameter is defined as reduction of systemic levels of oxidative stress markers and adhesion molecules (hsCRP, ICAM, VCAM, MCP-1, vWF, TGFß1, TNF-a, Interleukin-6, 8isoProstaglandinF2a) 22 weeks No
Secondary Number of cerebrovascular events 22 weeks No
Secondary Number of intermediate medical visits for cardiovascular reasons without hospitalization 22 weeks No
Secondary Number of hospitalization for cardiovascular reasons and GFR 22 weeks No
See also
  Status Clinical Trial Phase
Completed NCT05970120 - A Study of Intracardiac Ultrasound With the NUVISION NAV Ultrasound Catheter N/A
Recruiting NCT05416086 - iCLAS™ Cryoablation System Post-Market Clinical Follow-up (PMCF) Study N/A
Completed NCT03650556 - Safety and Effectiveness of TactiCath™ Contact Force, Sensor Enabled™ (TactiCath SE) Catheter for Ablation of Drug Refractory, Symptomatic, Persistent Atrial Fibrillation N/A
Recruiting NCT04085731 - Driver-guided Ablation of Persistent Atrial Fibrillatiom
Withdrawn NCT02344394 - Comparison of Hybrid Ablation and Pulmonary Vein Isolation Alone vs Hybrid Ablation With PVI Plus Catheter Ablation N/A
Completed NCT01694563 - ABLATE Post Approval Study - Synergy Ablation Lesions for Non-Paroxysmal Atrial Fibrillation N/A
Terminated NCT01683045 - Efficacy and Safety Study of the Estech COBRA® Surgical System to Treat Patients With a History of Irregular Heart Beats N/A
Active, not recruiting NCT03643224 - DiamondTemp™ System for the Treatment of Persistent Atrial Fibrillation N/A
Withdrawn NCT05093868 - Electrographic Flow Mapping Validation in Patients With Persistent Atrial Fibrillation (EVAL AF) N/A
Completed NCT05152966 - Feasibility Study of the FARAPULSE™ Cardiac Ablation System Plus in the Treatment of Persistent Atrial Fibrillation(PersAFOne II) N/A
Completed NCT05043883 - Automated Assessment of PVI Using a Novel EP Recording System N/A
Completed NCT04022954 - HD Mapping of Atrial Fibrillation in Asia Pacific
Active, not recruiting NCT06124690 - Persistent Atrial Fibrillation Without the Evidence of Low-voltage Areas N/A
Completed NCT06260670 - FLOW EVAL-AF: FLOW Mapping Electrogram VALidation in Patients With Persistent Atrial Fibrillation N/A
Not yet recruiting NCT05454111 - CARTO-Finder Guided Ablation Versus Multiscale Entropy Guided Ablation in Persistent Atrial Fibrillation N/A
Active, not recruiting NCT05077670 - Hybrid Characterization of Driver Sites During Atrial Fibrillation and Sinus Rhythm
Withdrawn NCT03835338 - WATCHMAN for Concomitant Left Atrial Appendage Electrical Isolation and Occlusion to Treat Persistent Atrial Fibrillation Rhythm N/A
Completed NCT02275104 - Multimodal Image Processing Software to Guide Cardiac Ablation Therapy N/A
Not yet recruiting NCT05565183 - Combined Study of ATrial Strain and Voltage by High Density Mapping in Young Patients With Atrial Fibrillation. N/A
Completed NCT02274857 - Randomized Evaluation of Atrial Fibrillation Treatment With Focal Impulse and Rotor Modulation Guided Procedures N/A